![]() | |
Clinical data | |
---|---|
Other names | GSK3640254 |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C43H67FN2O4S |
Molar mass | 727.08 g·mol−1 |
3D model (JSmol) | |
| |
|
Fipravirimat is an experimental drug for the treatment of HIV/AIDS. It belongs to a class of drugs known as maturation inhibitors.[1][2]
Fipravirimat was being developed by ViiV Healthcare, but development was stopped in 2023.[3]
See also
[edit]References
[edit]- ^ "Fipravirimat". PubChem. U.S. National Library of Medicine.
- ^ Dicker I, Jeffrey JL, Protack T, Lin Z, Cockett M, Chen Y, et al. (January 2022). "GSK3640254 Is a Novel HIV-1 Maturation Inhibitor with an Optimized Virology Profile". Antimicrobial Agents and Chemotherapy. 66 (1): e0187621. doi:10.1128/AAC.01876-21. PMC 8765437. PMID 34780263.
- ^ Waldron, James (2023-04-26). "GSK drops one of 2 maturation inhibitors in HIV pipeline". Retrieved 2023-09-18.